BP003743: Biotinylated Mouse PD-1/PDCD1 Protein with the C-hFc Tag
Source: The recombinant Biotinylated Mouse PD-1/PDCD1 Protein, (amino acids Leu25-Gln167) fused with a hFc tag at the C-terminus, was produced in HEK 293 cells.
Molecular Weight:The recombinant Biotinylated Mouse PD-1/PDCD1 protein with the hFc tag at the C-terminus has a predicted MW of 42.9 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
Activity: The affinity constant of 3.35 uM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.
Formulation: Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution: It is recommended to reconstitute the lyophilized recombinant Biotinylated Mouse PD-1/PDCD1 Protein in sterile H2O to a protein concentration not less than 100 ug/ml. Centrifuge the tube before opening.
Shipping: The recombinant Biotinylated Mouse PD-1/PDCD1 Protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 week, 2 to 8°C under sterile conditions after reconstitution.
6 months, -20 to -70°C under sterile conditions after reconstitution.
References of Biotinylated Mouse PD-1 Protein:
PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy
Liang Y, et al. Front Immunol. 2024 May 1;15:1367040. doi: 10.3389/fimmu.2024.1367040. PMID: 38745661
Biotinylated mouse PD-1/PDCD1 protein (His tag) and recombinant human PD-1 protein (Cat: 10377-H08H) were purchased from Sino Biological Inc (Beijing). Each well was filled with 200 nmol/L biotinylated PD-1 and FITC-labeled PPL-C peptides (at final concentrations of 40, 20, 10, 5, or 2.5 μmol/L) before 1.5 hours incubating at room temperature. The cells were treated with FITC-labeled PPL-C peptide for 60 minutes at 4°C on an inversion shaker in the presence of 200 nmol/L biotinylated PD-1. SAPE was added after two PBS washes, and the mixture was incubated for an additional 30 minutes. For the ELISA, 100 μL of mouse PD-L1 in PBS was coated in each well of a 96-well plate and incubated at 4°C overnight.
Tags: Mouse PD-1 Protein; recombinant Mouse PD-1/PDCD1 Protein
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
Weinberg F, et al. MAbs. 2024 Jan 1;16(1):2315653. doi: 10.1080/19420862.2024.2315653. PMID: 38379869
Endogenous levels of total PD-1 protein were detected by Western Blot (WB) using a commercial rabbit monoclonal antibody directed against the intracellular domain of PD-1. WB of peripheral blood mononuclear cells (PBMCs) treated with antibodies overnight ± increasing concentrations of batimastat. PD-1 surface expression and levels of PD-1 extracellular domain (ECD) in the supernatant of PBMCs stimulated and treated overnight with antibodies (mean ± SEM, n = 2). PDCD1 fold change compared to naive PBMCs of PBMCs activated with anti-CD3/CD28 for 72 h and activated PBMCs treated with antibodies overnight in the absence of anti-CD3/CD28. CTX-8371 matched or surpassed the activity of anti-PD-1 and PD-L1 benchmark antibodies in several in vitro T cell activation assays and outperformed clinically approved benchmarks in the subcutaneous MC38 colon and the B16F10 lung metastasis mouse tumor models.
Tags: Biotinylated Mouse PD-1/PDCD1 Protein price quote; low endotoxin Mouse PD-1 Protein
Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Ishikawa T, et al. Cancer Immunol Res. 2023 Oct 4;11(10):1313-1326. doi: 10.1158/2326-6066.CIR-22-0701. PMID: 37377896
His-tagged human PD-L1, mPD-L1, or cPD-L1 protein was immobilized on the Ni-NTA 96-well plate, and anti-cPD-L1 antibodies, 12C or 3C, with HRP-conjugated anti-canine IgG-specific secondary was added. OD450 was measured to quantify the amount of bound PD-L1 antibodies. The positive clones that blocked the interaction of cPD-L1/cPD-1 proteins are highlighted in red (A4 and B8). Representative images (at 18 hours) of the cPD-L1/cPD-1 blockade. Green fluorescent merged images of cPD-L1–expressing cells are shown.
Tags: Mouse PD-1/PDCD1 Protein for cell culture; activity of Biotinylated Mouse PD-1/PDCD1 Protein
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors
Zoltek N, et al. Cancer Immunol Res. 2023 May 3;11(5):636-650. doi: 10.1158/2326-6066.CIR-22-0801. PMID: 36656137
Seven different anti-PD-1 and PD-L1 monoclonal antibodies (mAbs) are now widely used in the United States to treat a variety of cancer types, but no clinical trials have compared them directly. Because many of these antibodies do not cross-react between mouse and human proteins, no preclinical models exist to address these questions. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Tumor growth curves were similar in HuNSG compared with nonhuman immune-engrafted NSG mice. Treatment with pembrolizumab, which targets programmed cell death protein 1, produced significant growth inhibition in both cell line-derived xenografts (CDX) and patient-derived xenografts (PDX) tumors in HuNSG but not in NSG mice.
Tags: Mouse PD-1/PDCD1 Protein signaling pathway; function of Mouse PD-1 Protein
Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody
Ito M, et al. Cancer Sci. 2022 Jan;113(1):312-323. doi: 10.1111/cas.15170. PMID: 34702924
After reconstitution of human immune systems by human hematopoietic stem cell transplantation (huNOG-FcγR-/- mice), four different programmed death-ligand 1 (PD-L1)-positive human cancer cell lines were tested. Among them, the growth of three cell lines was strongly suppressed by nivolumab in huNOG-FcγR-/- mice, but not in conventional huNOG mice. Immunohistochemistry demonstrated enhanced infiltration of human T cells into tumor parenchyma in only nivolumab-treated huNOG-FcγR-/- mice. Consistently, the number of human T cells was increased in the spleen in huNOG-FcγR-/- mice by nivolumab but not in huNOG mice. Human PD-L1 expression was strongly induced in the spleen of huNOG-FcγR-/- mice.
Tags: Mouse PD-1 Protein dose range; Biotinylated Mouse PD-1/PDCD1 Protein injection dose
For more references about biotinylated mouse PD-1 Protein please contact our scientific support team with message@sydlabs.com.
Syd Labs also provides the following PD-1/PDCD1 Protein:
Biotinylated Mouse PD-1 Protein
Human PD-1/PDCD1 Protein
Mouse PD-1/PDCD1 Protein
Cynomolgus PD-1/PDCD1 Protein
Canine PD-1/PDCD1 Protein
Human VEGF Protein
Human IL-2 Protein
Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1)
Syd Labs also provides the following PD-L1/PD-L2 Protein:
Human PD-L1/B7-H1 Protein
Cynomolgus PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein
Human PD-L2/B7-DC Protein
Biotinylated Human PD-L1 Protein